|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A phase II study of Tg4010 ( M va -Mucl -Il2) in association with chemotherapy in patients with stage III/IV non -small cell lung cancer显示文摘 | Ramlau R Quoix E Rolski J | 2008 | J Thorac Oncol2008，3，7： | 1 |
| 2 | A phase Ⅱ study of Tg4010 (Mva-Muc1-IL2)in association with chemotherapy in patients with stage Ⅲ/Ⅳ non-small cell lung cancer显示文摘 | Ramlau R Quoix E Rolski J | 2008 | Thorac Oncol2008，3，7： | 1 |
| 3 | Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) 显示文摘 | Pritchard KI Rolski J Papai Z | 2010 | Breast Cancer Res Treat2010，123，2： | 1 |
| 4 | Does Markov- modulation increase the risk? 显示文摘 | S ASMUSSEN A FREY T ROLSKI | 1995 | Astin Bulltin1995，25，： | 1 |
| 5 | Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer:results from the FIRST study显示文摘 | Robertson JF Llombart-Cussac A Rolski J | 2009 | J Clin Oncol2009，27，27： | 1 |
| 6 | A phase Ⅱ study of Tg4010 (Mva-Muel-Ⅰ12) in association with chemotherapy in patients with stage Ⅲ/Ⅳ Nan-small cell lung cancer显示文摘 | Ramlau R Quoix E Rolski J | 2008 | J Thorac Oneol2008，3，7： | 1 |
| 7 | Effects of palliative treatment with temozolomide in patients with high-grade gliomas显示文摘 | Ziobro M Rolski J Grela-Wojewoda A | 2008 | Neurol Neurochir Pol2008，42，3： | 1 |
| 8 | Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study 显示文摘 | Robertson JF Llombart-Cussac A Rolski J | 2009 | J Clin Oncol2009，27，45： | 1 |
| 9 | Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study 显示文摘 | Robertson JF Llombart-Cussac A Rolski J | 2009 | J Clin Oncol2009，27，27： | 1 |
| 10 | Risk theory in a periodic environment: The Cramer-Lundberg approximation and Lundberg's inequality显示文摘 | Asmussen S Rolski T | 1994 | Mathematics of Operation Research1994，19，2： | 1 |
| 11 | Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) 显示文摘 | Pritchard KI Rolski J Papai Z | 2010 | Breast Cancer Cancer Res Treat2010，123，2： | 1 |
| 12 | A phase II study of Tg4010 (Mva-Mucl-IL2) in association with chemotherapy in patients with stage Ill/IV non-small cell lung cancer显示文摘 | Ramlan R Quoix E Rolski J | 2008 | J Thorae Oncol2008，3，： | 1 |
| 13 | Expansions for Markov-modulated systems and approximations of rain probability显示文摘 | Blaszczyszyn B Rolski T | 1995 | J Appl Prob1995，33，： | 1 |
| 14 | Efficacy and safety of casopitant mesylate, a neurokinin 1 ( NK1 ) -receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial 显示文摘 | Grunberg SM Rolski J Strausz J | 2009 | Lancet Oncol2009，10，6： | 1 |
| 15 | Phase Ⅲ results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day Ⅳ/oral dosing regimen for chemotherapy-induced nausea and vomiting (C1NV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC) 显示文摘 | Strausz J Rolski J Aziz Z | 2000 | J Clin Oncol2000，，20： | 1 |
| 16 | Embolization of the renal artery in the treatment of Wilms' tumor显示文摘 | Jarmusz K Karwowski A Rolski M | 1983 | Nowotwory1983，33，2： | 1 |
| 17 | Randomized, dou-ble-blind , dose-ranging trial of the oral neurokinin-1 receptorantagonist casopitant mesylate for the prevention of cisplatin-in-duced nausea and vomiting 显示文摘 | ROILA F ROLSKI J RAMLAU R | 2009 | Ann Oncol2009，20，11： | 1 |
| 18 | Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study显示文摘 | Robertson JF Llombart-Cussac A Rolski J | 2009 | J Clin Oucol2009，27，27： | 1 |
| 19 | Efficacy and safety of casopitant mesylate, a neurokinin I (NKI )-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial显示文摘 | Gmnberg SM Rolski J Strausz J | 2009 | Lancet Oncol2009，10，6： | 1 |
| 20 | Results of a phaseII study comparing three dosing regimens of fulvestrantin postmenopausal women with advanced breast cancer(FINDER2)显示文摘 | Pritchard KI Rolski J Papai Z | 2010 | Breast Cancer Res Treat2010，123，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员